Ante Antengene

Why Qiming invested in Chinese in-licensing play Antengene

With a track record of bringing drugs to market in China, the founder of Chinese in-licensing play Antengene Corp. convinced Qiming Venture Partners to lead its $21 million series A round.

Antengene closed the round on Aug. 16. TF

Read the full 397 word article

User Sign In